Table 1.
Information items about cervical screening in invitation letters and leaflets.
| Information items | Norway | Saskatchewan, CA | Ontario, CA | Ireland | Finland | Manitoba, CA | Scotland | Northern Ireland | England | New Zealand | Sweden | Denmark | No. (%) of invitations (n = 12) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lifetime risk of developing cervical cancer | — | — | — | — | — | — | — | — | — | 1 | — | — | 1 (8) |
| Lifetime risk of dying from cervical cancer | — | — | — | — | — | — | — | — | — | 1 | — | — | 1 (8) |
| Survival from cervical cancer | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Relative risk reduction of death from cervical cancer | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Absolute risk reduction of death from cervical cancer | — | — | — | — | — | — | — | — | — | 1 | — | — | 1 (8) |
| Relative risk reduction of total mortality | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Absolute risk reduction of total mortality | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Relative risk reduction of developing cervical cancer | — | — | — | — | 1 | 1 | 1 | 1 | 1 | — | 1 | — | 6 (50) |
| Absolute risk reduction of developing cervical cancer | — | — | — | — | — | — | — | — | — | 1 | — | — | 1 (8) |
| Number needed to screen to avoid one death from cervical cancer | — | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Proportion of screened women who would be recalled as a result of an inadequate result | — | — | — | — | — | — | — | 1 | 1 | — | — | 1 | 3 (25) |
| Proportion of screened women who would be recalled as a result of an abnormal result | — | — | — | — | — | 1 | 1 | 1 | — | — | 1 | — | 4 (33) |
| Proportion of women with a positive test result who would have early stages of cervical cancer (CIN2+/CIN3+) (positive predictive value) | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 (8) |
| Overdiagnosis and overtreatment | — | — | — | — | 1 | 1 | 1 | — | 1 | — | 1 | 1 | 6 (50) |
| Quantification of overdiagnosis and overtreatment | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 (8) |
| Risks related to conisation | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 2 (17) |
| Quantification of risks related to conisation | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 (8) |
| Psychological distress related to false positive results | — | — | — | — | — | — | — | — | 1 | — | 1 | 1 | 3 (25) |
| Pain/discomfort related to the cytology test | — | — | — | 1 | 1 | — | 1 | 1 | 1 | 1 | 1 | 1 | 8 (67) |
| False positive results | — | — | — | 1 | — | — | — | 1 | — | 1 | — | 1 | 4 (33) |
| Quantification of false positive results | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 (8) |
| False negative results | — | — | 1 | 1 | — | — | 1 | 1 | 1 | — | — | 1 | 6 (50) |
| Quantification of false negative results | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 (8) |
| Total | — | — | 1 | 3 | 3 | 3 | 5 | 6 | 6 | 6 | 6 | 12 | |
| Pre-assigned date | — | — | — | — | 1 | — | — | — | — | — | 1 | — | 2 (17) |
| Appeals for participation | 1 | 1 | 1 | — | 1 | 1 | 1 | 1 | — | — | 1 | — | 8 (67) |